News | May 24, 2024
Taro shareholders approve merger with Sun Pharma
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Sun Pharma's Dadra facility receives OAI status from US FDA
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated
